A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer

PHASE1

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped After careful review of Taiho's ongoing portfolio and data obtained so far in the context of broader landscape of clinical development in NSCLC HER2mut, Sponsor has made a strategic decision to terminate this study and not based on safety concerns.

Conditions

Solid Tumor
Glioblastoma
Non-small Cell Lung Cancer
Breast Cancer

Interventions

DRUG: TAS2940
DRUG: TAS2940

Sponsor

Taiho Oncology, Inc.